Loading
A phase 2 trial of golidocitinib and sintilimab in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) is a phase 2, interventional study registered as NCT06198907 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 69 participants, started 2024-01 and due to reach its primary completion in 2026-12. Interventions recorded: Golidocitinib; Sintilimab; platinum doublet chemotherapy. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Overall response rate (ORR) (cohort1); Progression-free survival (PFS) (cohort2). Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) , Stage IIIB/IIIC (not suitable for concomitant chemoradiotherapy) or Stage IV according to AJCC 8th". Sites: China. No results are recorded here; the registry entry is the source.
Shares Golidocitinib, Dizal Pharmaceutical, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Sintilimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Sintilimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.